MS and Demyelinating Disorders

The neurologist at the University of Colorado offered an overview of the State of the Science Summit that was held on August 18, 2022, featuring a panel of expert clinicians. [WATCH TIME: 5 minutes]

Ahmed Obeidat, MD, PhD; Randall Schapiro, MD, FAAN; and Jeffrey Wilken, PhD, share their opinions on the utility of disease-modifying therapies to increase cognition and brain health in patients with multiple sclerosis.

Drs Randall Schapiro and Jeffrey Wilken explore the idea of cognition and brain health biomarkers in multiple sclerosis and provide imaging and diagnostic recommendations.

Benjamin Greenberg, MD, hypthothezies on where BTK inhibitors fit into the current treatment algorithim for the management of patients with multiple sclerosis.

Experts in neurology comment on the factors they consider when selecting and sequencing treatments for their patients with multiple sclerosis.

Here's some of what is coming soon to NeurologyLive® this week.

Chaired by Augusto Miravalle, MD, of the University of Colorado, the presentations also feature Barry Hendin, MD, of the Center for Neurology and Spine; Ilana B. Katz Sand, MD, of Mount Sinai; Brett Fling, PhD, of Colorado State University; and Gavin Giovannoni, MBBCh, PhD, of Queen Mary University of London. [WATCH TIME: 1 hour, 59 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Parkinson disease and movement disorders.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 26, 2022.

Between the 2 trials, patients showed significantly lower annualized relapse rates and mean number of gadolinium-enhancing lesions when treated with ublituximab relative to teriflunomide.

Drs Hesham Abboud and Benjamin Greenberg share their approach to treatment selection and highlight the importance of individualizing treatment and patient education.

Ahmed Obeidat, MD, PhD; Benjamin Greenberg, MD; and Hesham Abboud, MD, discuss the prevelance of multiple sclerosis and comment on the mechanisms of action and available drug classes utilized in disease management.

Experts in neurology provide insight into the impact multiple sclerosis can have on patients and hypothesize about initiating treatment before cognitive impairment is observed.

Ahmed Obeidat, MD, PhD; Randall Schapiro, MD, FAAN; and Jeffrey Wilken, PhD, discuss the impact of polypharmacy on cognitive health and share their thoughts on deciding when to cease treatments in patients with multiple sclerosis.

CXCL2 and CXCL12, known to induce B-cell proliferation and differentiation, were significantly higher in those with acute and remitted cases of NMOSD compared with controls.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is sleep disorders.

Neurology News Network for the week ending August 20, 2022. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 19, 2022.

Data assessing samples of deep cervical lymph node aspirates and blood suggest that germinal center activity was associated with clinical relapses in individuals with neuromyelitis optica spectrum disorder.

Data suggest that long-term treatment with immunosuppression therapies, such as rituximab, is generally appropriate for patients with neuromyelitis optica, though transverse myelitis might indicate a higher risk of relapse post discontinuation.

The coauthors of a study assessing costs associated with unused disease-modifying therapies shared their insight into the extended effects of unused treatments in MS, including the importance of transparency between physician and patient. [WATCH TIME: 12 minutes]

Clene Nanomedicine’s gold nanocrystal suspension treatment showed significant improvements in Low Contrast Letter Acuity and Multiple Sclerosis Functional Composite scores among individuals with relapsing multiple sclerosis.

Drs Randall Schapiro and Jeffrey Wilken provide insight into the risk factors and disease progression noted in patients with multiple sclerosis.

Experts in neurology comment on the lack of definition of cognitive impairment in multiple sclerosis, highlighting an inability to adequately screen for and measure this disease symptom.